HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy

Rather than relying on patient groups to make an impassioned plea, Roche aims to put doubts to rest around the controversial Duchenne muscular dystrophy gene therapy Elevidys with the rigor of another clinical study.

By FiercePharma · Apr 17, 2026 · via FiercePharma
Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy

Image: FiercePharma

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Small pools, big ideas: How the rare disease community is reimagining clinical trials
PipelineFierceBiotech ↗
Small pools, big ideas: How the rare disease community is reimagining clinical trials
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundre…
Apr 17, 2026
Qiagen launches latest diagnostic for bloodstream infections
PipelineFierceBiotech ↗
Qiagen launches latest diagnostic for bloodstream infections
Qiagen has moved into syndromic testing for bloodstream infections with the launch of its newest offering.…
Apr 17, 2026
Labcorp launches rapid fentanyl test with 48-hour detection window
PipelineFierceBiotech ↗
Labcorp launches rapid fentanyl test with 48-hour detection window
While fentanyl overdose deaths have been falling in recent years, use of the drug remains a major public healt…
Apr 17, 2026